METHOD FOR CARRYING OUT AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF ANTIBODIES IN A HUMAN BIOLOGICAL SAMPLE SPECIFIC TO THE SARS-COV2 HUMAN CORONAVIRUS, A TEST SYSTEM Russian patent published in 2021 - IPC G01N33/543 G01N33/68 

FIELD: medicine.

SUBSTANCE: inventions group relates to the diagnosis of immunity against COVID-19. Disclosed is a method for conducting an enzyme-linked immunosorbent assay for detecting antibodies in a biological sample specific to the human coronavirus SARS-COV2 using a test system, which provides for a reaction for IgM and IgG antibodies separately in different wells in the presence of a recombinant antigen containing the receptor-binding domain of the Spike protein human coronavirus SARS-COV2 (S-RBD), bound to the natural amino-terminal signal peptide and to the C-terminal hexahistidine tag of the Spike protein, while the antigen preparation is added to each well of the 96-well plate, incubated, the solution with the antigen is removed from the plate, washed with PBS-T cells, added to the wells with PBS-T with 4% BSA and incubated for 90 minutes, washed with PBS-T, applied to each well of the plate with antigen solution with PBS-T with 1% BSA, then 8 mcl of blood serum of the test patient, diluted in FSB-T with 1% BSA, is applied, incubated for 1 hour, the wells are washed 4 times with FSB-T, the conjugate of antibodies and enzyme is added, incubated for 40 minutes, washed with FSB-T 6 times, stained using TMB diluted in DMSO, sodium citrate buffer with the addition of 30% hydrogen peroxide, stop the color reaction by adding 0.25 M sulfuric acid and measure the optical density at a wavelength of 450-620 nm. Also disclosed is a test system for carrying out the specified method.

EFFECT: inventions group is suitable for high-precision determination of IgM and IgG antibodies in a biological sample.

2 cl, 6 tbl